{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008129","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.347081+00:00","generated_at":"2026-06-02T01:09:15.412635+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gain Therapeutics Q1 net loss $0.22/shr; cash $12.7M; GT-02287 Phase 1 SAD positive","bullets":["GAAP net loss per share $0.22 (Q1 2024) vs $0.43 (Q1 2023); narrower loss.","Cash, equivalents & marketable securities $12.7M as of March 31, 2024; cash runway guided into 2025.","R&D expenses $2.5M (down from $2.8M YoY); G&A expenses $1.9M (down from $2.5M YoY).","Positive SAD data for GT-02287; MAD part of Phase 1 initiated for GBA1 Parkinson’s disease.","Appointed Gene Mack as CFO and Jonas Hannestad, M.D., Ph.D. as CMO."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008129","json":"https://secwatch.observer/filing/0001558370-24-008129.json","markdown":"https://secwatch.observer/filing/0001558370-24-008129.md","text":"https://secwatch.observer/filing/0001558370-24-008129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000155837024008129/0001558370-24-008129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000155837024008129/ganx-20240514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:09:15.412635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}